Back to News
Jun 12, 2026 12:00 PM

AbbVie Says Nine-Year Data Reinforces Venetoclax Benefit In Leukemia Patients

AbbVie Inc. (NYSE:ABBV) stock is up slightly on Friday on new data presented at the European Hematology Association (EHA) 2026 Congress.

The company unveiled results from the Phase 3 CLL14 trial involving its venetoclax-based therapy for chronic lymphocytic leukemia (CLL).

New Venetoclax Data At EHA 2026

AbbVie announced new Phase 3 data on a fixed-duration venetoclax-based combination at the EHA 2026 Congress, showcasing the enduring safety and efficacy of the treatment.

Read Also:

AbbVie Thanks 'Excellent Start To 2026' To Immunology And Neuroscience Strength

A final analysis of the Phase 3 CLL14 trial compared venetoclax plus obinutuzumab to chlorambucil plus obinutuzumab in previously untreated patients with CLL and coexisting medical conditions.

The data found that venetoclax plus obinutuzumab significantly improved progression-free ...